Celgene offers promising preclinical data on two cytokine inhibitors.(Brief Article)

2002 MAY 8 - (NewsRx.com & NewsRx.net) -- Celgene Corp. (CELG) scientists presented data at the 93rd annual meeting of the American Association for Cancer Research from preclinical studies of IMiDs (Immunomodulatory Drugs) and SelCIDs (Selective Cytokine Inhibitory Drugs); the data demonstrate that IMiDs and SelCIDs have significant antitumor effects in in vivo models of solid tumor cancers.

"These findings validate our decision to accelerate the clinical development programs for our IMiD and SelCID pipelines in cancer," said David I. Stirling, PhD, chief scientific officer of Celgene Corp. "These data also provide valuable mechanistic insight as to how these two classes of orally available, anticancer compounds may benefit patients."

Celgene scientists and collaborators evaluated the ability of IMiDs to enhance the antitumor effects of an experimental cancer vaccine in a study titled "A Costimulatory Thalidomide Analog Enhances the Partial Anti-tumor Immunity of an Autologous Vaccination in a Model of Colorectal Cancer." In an in vivo model, healthy mice were first treated with an IMiD and then with an experimental cancer vaccine before ...